PURPOSE: Sickle cell disease (SCD) patients with asthma have an increased risk of death. Acute chest syndrome (ACS) is a major cause of mortality in patients with SCD, and ACS may be more common in SCD patients who smoke. The purpose of this study was to test the hypothesis that mortality in young adults with SCD would be greater than that of controls during a 10-year period and to determine whether asthma, reduced lung function, ACS episodes, and/or smoking predicted mortality during the follow-up period. METHODS: The outcomes during a 10-year period were ascertained of SCD patients and race-matched controls who had taken part in a pulmonary function study when they were between age 19 and 27 years. Smoking and asthma status and whether they had had ACS episodes were determined, and lung function was measured at the initial assessment. RESULTS: Seventy-five subjects with SCD were followed for 683 patient years. There were 11 deaths with a mortality rate of 1.6 deaths per 100 patient years, which was higher than that of the controls; one death in 47 controls was observed for 469 patient years with a mortality rate of 0.2 per 100 patient years (p = 0.03). There were no significant associations of body mass index, recurrent episodes of acute chest, steady state haemoglobin, or gender with mortality. Adjusting for baseline lung function in SCD patients, "current" asthma [hazard ratio (HR) 11.2; 95 % confidence interval (CI) 2.5-50.6; p = 0.002] and smoking [HR 2.7; (95 % CI 1.3-5.5); p = 0.006] were significantly associated with mortality during the 10-year period. CONCLUSIONS: Our results indicate that young adults with SCD should be discouraged from smoking and their asthma aggressively treated.
PURPOSE:Sickle cell disease (SCD) patients with asthma have an increased risk of death. Acute chest syndrome (ACS) is a major cause of mortality in patients with SCD, and ACS may be more common in SCDpatients who smoke. The purpose of this study was to test the hypothesis that mortality in young adults with SCD would be greater than that of controls during a 10-year period and to determine whether asthma, reduced lung function, ACS episodes, and/or smoking predicted mortality during the follow-up period. METHODS: The outcomes during a 10-year period were ascertained of SCDpatients and race-matched controls who had taken part in a pulmonary function study when they were between age 19 and 27 years. Smoking and asthma status and whether they had had ACS episodes were determined, and lung function was measured at the initial assessment. RESULTS: Seventy-five subjects with SCD were followed for 683 patient years. There were 11 deaths with a mortality rate of 1.6 deaths per 100 patient years, which was higher than that of the controls; one death in 47 controls was observed for 469 patient years with a mortality rate of 0.2 per 100 patient years (p = 0.03). There were no significant associations of body mass index, recurrent episodes of acute chest, steady state haemoglobin, or gender with mortality. Adjusting for baseline lung function in SCDpatients, "current" asthma [hazard ratio (HR) 11.2; 95 % confidence interval (CI) 2.5-50.6; p = 0.002] and smoking [HR 2.7; (95 % CI 1.3-5.5); p = 0.006] were significantly associated with mortality during the 10-year period. CONCLUSIONS: Our results indicate that young adults with SCD should be discouraged from smoking and their asthma aggressively treated.
Authors: Karl P Sylvester; Richard A Patey; Simon Broughton; Gerrard F Rafferty; David Rees; Swee Lay Thein; Anne Greenough Journal: Pediatr Pulmonol Date: 2007-02
Authors: K C Lødrup Carlsen; G Håland; C S Devulapalli; M Munthe-Kaas; M Pettersen; B Granum; M Løvik; K-H Carlsen Journal: Allergy Date: 2006-04 Impact factor: 13.146
Authors: Claudia R Morris; Jung H Suh; Ward Hagar; Sandra Larkin; D Anton Bland; Martin H Steinberg; Elliott P Vichinsky; Mark Shigenaga; Bruce Ames; Frans A Kuypers; Elizabeth S Klings Journal: Blood Date: 2007-09-11 Impact factor: 22.113
Authors: Marthe-Sandrine Eiymo Mwa Mpollo; Eric B Brandt; Shiva Kumar Shanmukhappa; Paritha I Arumugam; Swati Tiwari; Anastacia Loberg; Devin Pillis; Tilat Rizvi; Mark Lindsey; Bart Jonck; Peter Carmeliet; Vijay K Kalra; Timothy D Le Cras; Nancy Ratner; Marsha Wills-Karp; Gurjit K Khurana Hershey; Punam Malik Journal: J Clin Invest Date: 2015-12-21 Impact factor: 14.808
Authors: Jeffrey Glassberg; Caterina Minnitti; Caroline Cromwell; Lawrence Cytryn; Thomas Kraus; Gwen S Skloot; Jason T Connor; Adeeb H Rahman; William J Meurer Journal: Am J Hematol Date: 2017-06-05 Impact factor: 10.047
Authors: Adetola A Kassim; Amanda B Payne; Mark Rodeghier; Eric A Macklin; Robert C Strunk; Michael R DeBaun Journal: Blood Date: 2015-08-10 Impact factor: 22.113